Diagnostic Biomarker Expression Compared for Metastatic Tumors
By LabMedica International staff writers Posted on 25 Sep 2019 |
Image: The Ventana Discovery ultra biomarker platform stainer (Photo courtesy of Roche Diagnostics).
Metastatic mucinous tumors pose a unique diagnostic challenge for the surgical pathologist as their morphologic and clinical characteristics are often nonspecific. The colorectum is the most common site of origin.
Historically, the immunophenotypic characteristics of mucinous tumors demonstrate a great degree of overlap across primary sites. Nonspecific staining characteristics of low-molecular weight-cytokeratins (CK7, CK20) have been well documented in mucinous tumors, including those of ovarian, colorectal, and pulmonary origin.
Pathologists at the University of New Mexico School of Medicine (Albuquerque, NM, USA) and their colleagues have presented a head-to-head comparison of special AT-rich sequence-binding protein 2 (SATB2) and caudal type homeobox 2 (CDX2) expression in a diverse array of primary mucinous tumors. SATB2 and CDX2 immunohistochemical stains were performed on whole sections from 44 mucinous colorectal carcinomas and 175 non-colorectal mucinous tumors. A nuclear scoring system measuring intensity (0–3+) and percentage staining (0 = <5%, 1 = 5%–49%, 2 = ≥50%) was implemented, producing an additive histologic score (H-score). The Ventana Discovery platform (Ventana Medical Systems, Tucson, AZ, USA) was used in application of the SATB2 and CDX2 antibodies.
The scientists reported that SATB2 demonstrated acceptable accuracy at low to moderate expression levels (H-scores of 1–4). With these H-score cutoffs, overall accuracy was greater than 90%. In contrast, CDX2's accuracy rivaled that of SATB2 only at an H-score of 5 (89.0%), as its specificity suffered at lower expression levels (<70.0% at H-scores of 1–4). Using a moderate H-score cutoff of 3 or higher, significant differences for both sensitivity and specificity were identified between SATB2 and CDX2, though these stains were near equivalent when each was interpreted as positive at its respective optimal H-score (SATB2 ≥ 3 and CDX2 = 5).
The authors concluded that SATB2 is a more accurate marker of colorectal origin across a variety of expression levels compared with CDX2 when applied to mucinous tumors from a host of primary sites. However, these stains are near equivalent when each is interpreted at its optimal expression level. The study was published in the September 2019 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
University of New Mexico School of Medicine
Ventana Medical Systems
Historically, the immunophenotypic characteristics of mucinous tumors demonstrate a great degree of overlap across primary sites. Nonspecific staining characteristics of low-molecular weight-cytokeratins (CK7, CK20) have been well documented in mucinous tumors, including those of ovarian, colorectal, and pulmonary origin.
Pathologists at the University of New Mexico School of Medicine (Albuquerque, NM, USA) and their colleagues have presented a head-to-head comparison of special AT-rich sequence-binding protein 2 (SATB2) and caudal type homeobox 2 (CDX2) expression in a diverse array of primary mucinous tumors. SATB2 and CDX2 immunohistochemical stains were performed on whole sections from 44 mucinous colorectal carcinomas and 175 non-colorectal mucinous tumors. A nuclear scoring system measuring intensity (0–3+) and percentage staining (0 = <5%, 1 = 5%–49%, 2 = ≥50%) was implemented, producing an additive histologic score (H-score). The Ventana Discovery platform (Ventana Medical Systems, Tucson, AZ, USA) was used in application of the SATB2 and CDX2 antibodies.
The scientists reported that SATB2 demonstrated acceptable accuracy at low to moderate expression levels (H-scores of 1–4). With these H-score cutoffs, overall accuracy was greater than 90%. In contrast, CDX2's accuracy rivaled that of SATB2 only at an H-score of 5 (89.0%), as its specificity suffered at lower expression levels (<70.0% at H-scores of 1–4). Using a moderate H-score cutoff of 3 or higher, significant differences for both sensitivity and specificity were identified between SATB2 and CDX2, though these stains were near equivalent when each was interpreted as positive at its respective optimal H-score (SATB2 ≥ 3 and CDX2 = 5).
The authors concluded that SATB2 is a more accurate marker of colorectal origin across a variety of expression levels compared with CDX2 when applied to mucinous tumors from a host of primary sites. However, these stains are near equivalent when each is interpreted at its optimal expression level. The study was published in the September 2019 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
University of New Mexico School of Medicine
Ventana Medical Systems
Latest Pathology News
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases
- Bioinformatics Tool to Identify Chromosomal Alterations in Tumor Cells Can Improve Cancer Diagnosis
- Coin-Sized Device Rapidly Isolates Blood Plasma for Quicker and More Precise Clinical Diagnoses